Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Eche

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Annales De Biologie Clinique|August 7, 2009
[PSA kinetics after radiotherapy]J-M Riedinger, N Eche, J-M Bachaud, et al.
Gynecologic Oncology|March 11, 2008
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric studyJ M Riedinger, N Eche, J P Basuyau, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2006
Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinomaF Courbon, S Zerdoud, D Bastie, et al.
Breast Cancer Research and Treatment|October 1, 1991
65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsivenessS Jozan, A M Julia, A Carretie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Annales De Biologie Clinique|August 7, 2009
[PSA kinetics after radiotherapy]J-M Riedinger, N Eche, J-M Bachaud, et al.
Gynecologic Oncology|March 11, 2008
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric studyJ M Riedinger, N Eche, J P Basuyau, et al.
Thyroid : Official Journal of the American Thyroid Association|October 18, 2006
Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinomaF Courbon, S Zerdoud, D Bastie, et al.
Breast Cancer Research and Treatment|October 1, 1991
65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsivenessS Jozan, A M Julia, A Carretie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcomeJ M Riedinger, F Bonnetain, J P Basuyau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2006
CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyJ M Riedinger, J Wafflart, G Ricolleau, et al.
British Journal of Cancer|August 14, 2003
Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Bulletin Du Cancer|November 21, 2000
[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group]J P Basuyau, M P Blanc-Vincent, J M Bidart, et al.
Annales De Biologie Clinique|April 9, 2002
[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]J M Riedinger, N Eche, J P Basuyau, et al.
Bulletin Du Cancer|October 2, 2001
[Standards, options and recommendations for blood tumor markers in thyroid cancers]M F Pichon, J P Basuyau, G Gory-Delabaere, et al.
Pageof 3